HSCS

DEFA14A - HeartSciences Inc. (0001468492) (Filer)

8-K - HeartSciences Inc. (0001468492) (Filer)

DENVER, June 23, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological innovation, companies that successfully execute during periods of rapid change often find themselves at important inflection points. NeOnc Technologies Approaches Major Clinical Catalyst NeOnc Technologies (NASDAQ:NTHI) has emerged as a company attracting attention within the neuro-oncology sector after announcing that the Department of Health–Abu Dhabi granted Investigational New Drug authorization for its NEO100 program. The approval covers multiple protocols spanning adult Pha

DEFA14A - HeartSciences Inc. (0001468492) (Filer)

8-K - HeartSciences Inc. (0001468492) (Filer)

Combined company expected to operate under the Fortitude brand and to trade on Nasdaq under the ticker symbol "TUDE"; transaction expected to close in H2 2026 Upon completion of the transaction, Fortitude believes it will be the first publicly traded venture mining platform with a track record of identifying high-conviction, early-stage Proof-of-Work opportunities Fortitude Mining Holdings, Inc. ("Fortitude"), a vertically-integrated digital asset mining platform anchored in Zcash, and HeartSciences Inc. (NASDAQ:HSCS) ("HeartSciences"), an AI-powered medical technology company, today announced that they have entered into a definitive merger agreement to combine in an all-stock transacti

Southlake, TX, June 11, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), today announced the grant by the European Patent Office (EPO) of European Patent No. EP4252651, titled "Electrocardiogram-Based Assessment of Diastolic Function." The patent covers machine-learning models and methods for computing quantitative estimates of echocardiogram parameters indicative of diastolic function using ECG data and patient demographic parameters. "Securing European patent protectio

Southlake, TX, June 02, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), today announced the commercial release of MyoVista Insights™ version 1.3, a major platform update that introduces the MyoVista Insights AI-ECG Algorithm Marketplace. The Marketplace enables third-party algorithm results to be integrated into the MyoVista Insights platform, beginning with an FDA-cleared AI-ECG model from Bunkerhill Health. The Bunkerhill ECG-EF model enables clinicians to detect reduc

253G2 - HeartSciences Inc. (0001468492) (Filer)

Southlake, TX, May 19, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), today announced that it has entered into a commercial agreement with North Shore Health, a community hospital serving Cook County, Minnesota and the surrounding region, to deploy the MyoVista Insights™ platform. North Shore Health is part of the Cibolo Rural Health Networks ("Cibolo Health") network, which previously selected MyoVista Insights as its endorsed ECG management platform for hospitals wit

8-K - HeartSciences Inc. (0001468492) (Filer)

Southlake, TX, May 05, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), today announced that it has signed a commercial agreement with St. Vincent Health, a Critical Access Hospital serving Lake County, Colorado, to deploy the MyoVista Insights™ platform. The agreement marks an important commercial milestone for HeartSciences, representing the Company's first mainstream revenue-generating deployment of MyoVista Insights, building on previously announced reference and ear

QUALIF - HeartSciences Inc. (0001468492) (Filer)

253G2 - HeartSciences Inc. (0001468492) (Filer)

Southlake, TX, April 14, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company") a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), would like to remind its shareholders to vote ahead of its upcoming Annual Meeting of Shareholders (the "Annual Meeting") which will be held virtually on Thursday, April 30, 2026, at 10:00 a.m. Eastern Time. All shareholders of record of HeartSciences' outstanding shares of common stock and Series C preferred stock at the close of business on March 6, 2026, are entitled to participate and vote at the

1-A POS - HeartSciences Inc. (0001468492) (Filer)

8-K - HeartSciences Inc. (0001468492) (Filer)

Southlake, TX , March 25, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.  (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), today announced that its MyoVista Insights™ platform has received Epic Toolbox designation for the ECG Management System category. MyoVista Insights is a cloud-native ECG management and analysis platform designed to enhance workflow efficiency and support clinical decision-making. The platform supports integration with hospital information systems and electronic health records ("EHRs"), including

Southlake, TX, March 24, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.  (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), will present at Investor Summit Group Virtual Conference, March 25, 2026 at 12:30 pm ET. Hosted by Investor Summit Group, a premier platform connecting microcap companies with leading investors, the event provides a highly efficient forum for emerging growth companies to engage directly with institutional investors, family offices, and high-net-worth individuals. Event Details: Conference: Inves

DEFA14A - HeartSciences Inc. (0001468492) (Filer)

DEF 14A - HeartSciences Inc. (0001468492) (Filer)

8-K - HeartSciences Inc. (0001468492) (Filer)

Southlake, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.  (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), today reported financial results for its fiscal third quarter ended January 31, 2026 ("FQ3 2026") and provided a business update. Third Quarter and Recent Highlights During the third quarter and subsequent period, the Company continued advancing the commercialization of its MyoVista Insights™ healthcare IT platform and submitted its MyoVista® wavECG™ device to the U.S. Food and Drug Administra

10-Q - HeartSciences Inc. (0001468492) (Filer)

PRE 14A - HeartSciences Inc. (0001468492) (Filer)